3 years on from their introduction, one of the most fascinating elements of the GLP-1 drug rollout, is the variation in responses from one person to another, something I looked at in this recent piece for the Irish Examiner
Sheela Magge, director of pediatric endocrinology at Johns Hopkins Medicine in Baltimore, has seen an increase in cases of more severe obesity-related conditions in children, including non-alcoholic fatty liver disease
The findings highlight an opportunity to increase use of GLP-1s for weight and disease management and, in doing so, increase access to GLP-1s among adults who smoke, Kristy A
The dosing protocols differ significantly between the two medications, with tirzepatide starting at 2.5 mg weekly and potentially escalating to 15 mg based on tolerance and response
You may need to draw slightly more to reach your target after expelling the air
Personalized Treatment Plans Every patient receives a plan tailored to their unique bloodwork, lifestyle, and goalsnever a one-size-fits-all prescription
.webp)
